RNA interference mediating small RNA molecules
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C07H-021/02
C12N-015/85
C12N-015/113
A61K-048/00
C12N-015/10
C12N-015/11
A61K-009/00
A61K-038/00
출원번호
US-0879300
(2010-09-10)
등록번호
US-8993745
(2015-03-31)
우선권정보
EP-00126325 (2000-12-01)
발명자
/ 주소
Tuschl, Thomas
Elbashir, Sayda Mahgoub
Lendeckel, Winfried
출원인 / 주소
Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.
대리인 / 주소
Lando & Anastasi, LLP
인용정보
피인용 횟수 :
1인용 특허 :
43
초록▼
Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short inter
Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
대표청구항▼
1. A eukaryotic cell or a eukaryotic non-human organism comprising at least one double-stranded RNA molecule capable of mediating RNA interference, wherein: (i) each RNA strand of the RNA molecule independently consists of 19 to 25 nucleotides in length;(ii) at least one RNA strand of the RNA molecu
1. A eukaryotic cell or a eukaryotic non-human organism comprising at least one double-stranded RNA molecule capable of mediating RNA interference, wherein: (i) each RNA strand of the RNA molecule independently consists of 19 to 25 nucleotides in length;(ii) at least one RNA strand of the RNA molecule forms a single-stranded 3′-overhang from 1 to 5 nucleotides;(iii) a strand of the RNA molecule is at least 85% identical to a target mRNA molecule in the double-stranded portion of the RNA molecule; and(iv) the RNA molecule comprises at least one nucleotide analogue. 2. The cell or organism of claim 1, wherein the cell is a mammalian cell. 3. The cell or organism of claim 1, wherein the cell is chosen from an embryonic cell, a pluripotent stem cell, a tumor cell or a virus-infected cell. 4. The cell or organism of claim 1, wherein the cell is a human cell. 5. The cell or organism of claim 1, which is a plant cell or organism. 6. The cell or organism of claim 1, wherein the double-stranded RNA molecule mediates RNA interference of a target gene chosen from a pathogen-associated gene, a viral gene, a tumor-associated gene, or an autoimmune disease-associated gene. 7. The cell or organism of claim 1, wherein a strand of the RNA molecule is identical to the target mRNA molecule in the double-stranded portion of the RNA molecule. 8. The cell or organism of claim 1, wherein at least one of the RNA strands of the RNA molecule forms a 3′-overhang from 1-3 nucleotides in length. 9. The cell or organism of claim 8, wherein at least one of the strands of the RNA molecule forms a 3′-overhang which is 2 nucleotides in length. 10. The cell or organism of claim 8, wherein each strand of the RNA molecule consists of 20 to 22, or 21 to 23 nucleotides in length. 11. The cell or organism of claim 8, wherein at least one of the strands consists of 21 nucleotides in length. 12. The cell or organism of claim 1, wherein the nucleotide analogue is selected from a sugar- or a backbone-modified ribonucleotide, or a combination thereof. 13. The cell or organism of claim 1, wherein the nucleotide analogue is a sugar-modified ribonucleotide, wherein the 2′-OH group is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2 or CN, wherein R is C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and halo is F, Cl, Br or I. 14. The cell or organism of claim 1, wherein the nucleotide analogue is a backbone-modified ribonucleotide containing a phosphorothioate group. 15. The cell or organism of claim 1, wherein said double-stranded RNA molecule comprises a 2′-F sugar modified ribonucleotide, a 2′-OMe sugar modified ribonucleotide and a phosphorothioate backbone modified ribonucleotide. 16. The cell or organism of claim 1, wherein the at least one nucleotide analogue is located at the 5′-end, the 3′-end, or both, of the double stranded RNA molecule. 17. The cell or organism of claim 16, wherein the nucleotide analogue is located in the 3′-overhang of the double-stranded RNA molecule. 18. The cell or organism of 17, wherein the nucleotide analogue of the 3′-overhang is selected from a sugar- or a backbone-modified ribonucleotide, or a combination thereof. 19. The cell or organism of claim 17, wherein the nucleotide analogue of the 3′-overhang is a sugar-modified ribonucleotide, wherein the 2′-OH group is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, N(R)2 or CN, wherein R is C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl and halo is F, Cl, Br or I. 20. The cell or organism of claim 17, wherein the nucleotide analogue of the 3′-overhang is a backbone-modified ribonucleotide containing a phosphorothioate group. 21. The cell or organism of claim 17, wherein the 3′-overhang of the double-stranded RNA molecule comprises a 2′-deoxythymidine or a nucleotide lacking a 2′-hydroxyl in a sugar. 22. The cell or organism of claim 17, wherein the 3′-overhang of the double-stranded RNA molecule comprises a nucleobase-modified ribonucleotide chosen from a non-naturally-occurring nucleobase modified at the 5-position; an adenosine or a guanosine modified at the 8-position; or an O- or an N-alkylated nucleotide. 23. The cell or organism of claim 1, wherein the double-stranded RNA molecule consists of a single double-stranded region and a single-stranded region of 1 to 3 nucleotides at the 3′ end of at least one of the strands of said double-stranded RNA molecule. 24. The cell or organism of claim 1, wherein one strand of the double-stranded RNA molecule is blunt-ended. 25. The cell or organism of claim 1, wherein the at least one single-stranded 3′-overhang has been stabilized against degradation. 26. The cell or organism of claim 25, wherein said single-stranded 3′-overhang comprises one or more nucleotide analogues. 27. The cell or organism of claim 26, wherein the nucleotide analogue of said single-stranded 3′-overhang is a sugar-modified ribonucleotide, wherein the 2′-OH group of said sugar-modified ribonucleotide is replaced by a group selected from the group consisting of H, OR, R, halo, SH, SR, NH2, NHR, NR2 and CN, wherein R is C1-C6 alkyl, C2-C6 alkenyl or alkynyl and halo is F, Cl, Br or I. 28. The cell or organism of claim 27, wherein said single-stranded 3′-overhang further comprises a backbone-modified ribonucleotide containing a phosphorothioate group. 29. The cell or organism of claim 1, wherein said double-stranded RNA molecule is not enzymatically processed. 30. The cell or organism of claim 1, wherein said double-stranded RNA molecule is not enzymatically cleaved. 31. The cell or organism of claim 1, wherein said RNA molecule is isolated, non-enzymatically processed, prior to being introduced to the cell or organism. 32. The cell or organism of claim 1, wherein said RNA molecule is in a pharmaceutical composition prior to being introduced to the cell or organism. 33. The cell or organism of claim 1, wherein said RNA molecule has been introduced into the cell or the organism by carrier mediated delivery. 34. The cell or organism of claim 33, wherein said carrier mediated delivery comprises a liposomal carrier. 35. The cell or organism of claim 1, wherein said RNA molecule has been introduced into the cell or the organism by injection. 36. A eukaryotic cell comprising at least one double-stranded RNA molecule capable of mediating RNA interference, wherein: (i) each RNA strand of the RNA molecule independently consists of 19 to 25 nucleotides in length;(ii) at least one RNA strand of the RNA molecule forms a single-stranded 3′-overhang from 1 to 5 nucleotides;(iii) a strand of the RNA molecule is at least 85% identical to a target mRNA molecule in the double-stranded portion of the RNA molecule; and(iv) said RNA molecule is isolated, non-enzymatically processed, prior to being introduced into the cell. 37. The cell of claim 36, wherein said RNA molecule is prepared by chemical synthesis. 38. The cell of claim 36, wherein a strand of the RNA molecule is identical to the target mRNA molecule in the double-stranded portion of the RNA molecule. 39. A eukaryotic cell comprising at least one double-stranded RNA molecule capable of mediating RNA interference, wherein: (i) each RNA strand of the RNA molecule independently consists of 19 to 25 nucleotides in length;(ii) at least one strand of the RNA molecule forms a single-stranded 3′-overhang from 1 to 5 nucleotides, wherein said 3′-overhang that has been stabilized against degradation; and(iii) a strand of the RNA molecule is at least 85% identical to a target mRNA molecule in the double-stranded portion of the RNA molecule. 40. The cell of claim 39, wherein a strand of the RNA molecule is identical to the target mRNA molecule in the double-stranded portion of the RNA molecule. 41. A eukaryotic cell comprising at least one double-stranded RNA molecule capable of mediating RNA interference, wherein: (i) each strand of the RNA molecule independently consists of 19 to 25 nucleotides in length;(ii) at least one strand of the RNA molecule forms a single-stranded 3′-overhang from 1 to 5 nucleotides, wherein said 3′-overhang comprises one or more nucleotide analogues; and(iii) a strand of the RNA molecule is identical to a target mRNA molecule in the double-stranded portion of the RNA molecule.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Chris A. Buhr ; Mark Matteucci, 2' Modified oligonucleotides.
Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Carlsbad CA) Cowsert Lex M. (Carlsbad CA), Antisense oligonucleotide inhibition of papillomavirus.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Noonberg Sarah B. (Berkeley CA) Hunt C. Anthony (San Francisco CA), In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides deriv.
Thompson Peter (Danville CA) Lund-Johannsen Fridjtof (Fremont CA), Method for identifying cells committed to apoptosis by determining cellular phosphotyrosine content.
Francis P. Tally ; Jianshi Tao ; Philip A. Wendler ; Gene Connelly ; Paul L. Gallant ; Xiaoyu Shen ; Jiansu Zhang, Method for identifying validated target and assay combinations for drug development.
Eckstein Fritz (Gottingen DEX) Pieken Wolfgang (Boulder CO) Benseler Fritz (Gleichen/Etzborn DEX) Olsen David B. (West Point PA) Williams David M. (Cambridge GB2) Heidenreich Olaf (Gottingen DEX), Modified ribozymes.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Draper Kenneth G. (Boulder CO) Crooke Stanley T. (Carlsbad CA) Mirabelli Christopher K. (Encinitas CA) Ecker David J. (Leucadia CA) Hanecak Ronnie C. (San Clemente CA) Anderson Kevin P. (Carlsbad CA), Oligonucleotide therapies for modulating the effects of herpes viruses.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.